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Genome wide association studies revealed an association of the single nucleotide polymor-
phism rs11708067 within the ADCY5 gene—encoding adenylate cyclase 5—with increased
type 2 diabetes (T2D) risk and higher fasting glucose. However, it remains unclear whether
the association between ADCY5 variants and glycemic traits may involve adipose tissue
(AT) related mechanisms. We therefore tested the hypothesis that ADCY5mRNA expres-
sion in human and mouse AT is related to obesity, fat distribution, T2D in humans and high
fat diet (HFD) in mice. We measured ADCY5mRNA expression in paired samples of viscer-
al and subcutaneous adipose tissue from 244 individuals with a wide range of body weight
and parameters of hyperglycemia, which have been genotyped for rs11708067. In addition,
AT ADCY5mRNA was assessed in C57BL/6NTac which underwent a 10 weeks standard
chow (n = 6) or high fat diet (HFD, n = 6). In humans, visceral ADCY5 expression is signifi-
cantly higher in obese compared to lean individuals. ADCY5 expression correlates with
BMI, body fat mass, circulating leptin, fat distribution, waist and hip circumference, but not
with fasting plasma glucose and HbA1c. Adcy5 expression in mouse AT is significantly
higher after a HFD compared to chow (p<0.05). Importantly, rs11708067 is not associated
with ADCY5mRNA expression levels in either fat depot in any of the genetic models tested.
Our results suggest that changes in AT ADCY5 expression are related to obesity and fat dis-
tribution, but not with impaired glucose metabolism and T2D. However, altered ADCY5 ex-
pression in AT does not seem to be the mechanism underlying the association between
rs11708067 and increased T2D risk.
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Introduction
In a meta-analysis of genome wide association studies (GWAS) several genetic loci associated
with fasting diabetes-related quantitative traits (fasting plasma glucose, fasting plasma insulin,
beta-cell function (HOMA-B) and insulin resistance (HOMA-IR) have been identified [1]. Sin-
gle nucleotide polymorphisms (SNPs) within the ADCY5 gene, which encodes adenylate cy-
clase 5, are associated with elevated fasting glucose and increased risk to develop type 2
diabetes (T2D) [1]. Recently, it has been shown that ADCY5mRNA expression in islets is
lower in carriers of high risk alleles at rs11708067 and maybe linked to fasting hyperglycemia
and higher T2D risk [2]. Associations between rs11708067 lower birth weight [3] and gesta-
tional diabetes has also been shown [4]. Moreover, associations between the major allele (C) of
ADCY5 variant rs2877716 and decreased fasting plasma insulin, peak insulin and increased
QUICKI and Matsuda insulin sensitivity index were found in obese children [5].
ADCY5 is a member of the adenylate cyclase family, which consists of twelve domain trans-
membrane proteins that catalyzes the conversion of ATP to cyclic AMP, the second messenger
for G protein coupled receptors [6]. Adenylate cyclases (AC) are ATP-pyrophoshate lyases
which convert Adenosine triphosphate (ATP) into the second messenger cyclic adenosine mo-
nophosphate (cAMP) and pyrophosphate [6]. cAMP itself plays an important role in glycogen,
sugar and lipid metabolism by intracellular signal transduction [6]. ADCY5 has been described
to mediate renin release [7], influence heart rate [8] and plays a role in dopamine homeostasis
in the central nervous system [9].
Interestingly, ADCY5 has been identified in an exome sequencing study as candidate gene
for familial exceptional longevity [10]. In this context, transgenic expression of miR-17 causes
ADCY5 silencing which contributes to extended lifespan of mice via promotion of autophagy
and repression cellular senescence and apoptosis [11]. Adipose tissue mass, distribution and
function are closely related to longevity [12] and the individual risk to develop metabolic dis-
eases including T2D [13]. Despite the robust association of ADCY5 variants and metabolic
traits, potential mechanisms underlying the effects of these polymorphic variants at the level of
adipose tissue need to be explored.
We therefore tested the hypotheses that (1) ADCY5mRNA expression in adipose tissue is
related to obesity, fat distribution and T2D in humans, (2) ADCY5 rs11708067 genotype con-
tributes to alterations in ADCY5 expression and phenotype and (3) high fat feeding of mice re-
sults in ADCY5 expression changes in AT.
Materials and Methods
Study participants
Paired samples of visceral (VAT) and subcutaneous (SAT) adipose tissue were obtained from
244 Caucasian men (n = 87) and women (n = 157), who underwent open abdominal surgery
for weight reduction surgery (n = 188), abdominal injuries (n = 11), explorative laparotomy
(n = 12), cholecystectomy (n = 24) or appendectomy (n = 9) at three medical centers (Universi-
ty of Leipzig, Municipal Clinic Dresden-Neustadt and Municipal Clinic Karlsruhe, all Ger-
many). The mean age of study participants was 51 years (49±15 in women and 53±14 in men)
and mean BMI was 42kg/m2 (36.2±14.4 in women and 39.7±12.7 in men) (Table 1). All study
participants had a stable weight with no fluctuations of more than 2% of the body weight for at
least three months before surgery. Patients with severe conditions including generalized in-
flammation or end stage malignant diseases were excluded from the study. Samples of visceral
and subcutaneous adipose tissue were immediately frozen in liquid nitrogen after explantation.
Visceral AT samples were obtained from the upper left part of the omentum. The study was
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approved by the Ethics Committee of the University of Leipzig (Reg. number: 017–12–
23012012). All participants gave written informed consent before taking part in the study.
Measurement of body fat content, glucose metabolism, insulin sensitivity
BMI was calculated as weight divided by squared height. Hip circumference was measured
over the buttocks; waist circumference was measured at the midpoint between the lower ribs
and iliac crest. Percentage body fat was measured by dual X-ray absorptiometry (DEXA) and
or bioimpedance analysis. Abdominal visceral and subcutaneous fat areas were calculated
using computed tomography (CT) or MRI scans at the level of L4–L5 as previously described
[14, 15]. Three days before the oral tolerance test (OGTT), patients documented a high-
carbohydrate diet in diet protocols. The OGTT was performed after an overnight fast with 75 g
standardized glucose solution (Glucodex Solution 75 g; Merieux, Montreal, QC, Canada). Ve-
nous blood samples were taken at 0, 60, and 120 min for measurements of plasma glucose con-
centrations. Insulin sensitivity was assessed using the HOMA-IR index or with the euglycemic-
hyperinsulinemic clamp method as described previously [16].
Analyses of laboratory parameters in blood samples
All baseline blood samples were collected between 8 and 10 am after an overnight fast to deter-
mine glucose, insulin and standard laboratory parameters. Plasma insulin was measured with a
two-site chemiluminescent enzyme immunometric assay for the IMMULITE automated ana-
lyzer (Diagnostic Products Corporation, Los Angeles, CA, USA). Serum high-sensitive CRP,
adiponectin, and leptin, were measured as previously described [17].
Table 1. Anthropometric andmetabolic characteristics of participants in the study of adipose tissue ADCY5mRNA expression (n = 244).
Men Women T2D No diabetes Lean Obese
N 87 157 80 164 43 175
Age (years) 53±14 49±15 53±12 49±16 48±12.9 51.2±15.7
Body weight (kg) 115±49 108±37 140±39* 111±42 63±10.2*** 141.1±31.6
Height (m) 1.78±0.06** 1.64±0.07 1.70±0.1 1.69±0.1 1.70±0.1 1.70±0.1
BMI (kg/m²) 39.7±12.7 36.2±14.4 48±13** 39±13 21.9±2.8*** 48.7±9.4
Visceral fat area (cm²) 247±181 254±181 415±151** 182±144 47.1±31*** 325±162
SC fat area (cm²) 1040±811 1272±778 1519±611* 1048±825 55±26*** 1626±490
CT ratio 0.5±0.7 0.33±0.42 0.48±0.81 0.4±0.4 1.1±0.9** 0.2±0.1
Body fat (%) 34±14 38±10 42±10* 34±12 19±3.5** 42.7±7.2
Waist (cm) 128±35* 119±30 144±27** 111±29 77.9±15*** 137.0±23.3
Hip (cm) 129±32 130±29 138±25** 126±31 87±9.7*** 144.8±20.3
WHR 0.99±0.1* 0.91±0.1 1.05±0.08* 0.9±0.1 0.89±0.1** 0.95±0.1
Fasting plasma glucose (mmol/l) 5.3±0.6 5.3±0.5 7.7±2.0** 5.3±0.5 5.6±1.1 6.2±1.7
Data are means ± SD.
*p<0.05,
**p<0.01,
***p<0.001 for comparisons between men and women, individuals with T2D versus no diabetes or lean versus obese.
BMI, body mass index, WHR, waist-hip ratio, 2h oGTT, 2 hour oral glucose tolerance test, GIR, glucose infusion rate, hsCRP, high sensitive C-reactive
protein, HDL, high-density lipoprotein, LDL, how-density lipoprotein, SC subcutaneous
doi:10.1371/journal.pone.0120742.t001
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Characterization of adipose tissue samples
During surgery, adipose tissue samples were taken from the abdominal SC and the intraab-
dominal omental fat depots at defined locations. Adipose tissue was analyzed as a whole (im-
mediately frozen in liquid nitrogen after explantation) for histology and mRNA expression
analyses. Additional adipose tissue samples were collected in 37°C PBS buffer and adipocytes
were isolated by collagenase (1 mg/ml) digestion. Immediately after collagenase digestion, adi-
pocytes were fixed with osmic acid, incubated for 48 hours at 37°C. To determine adipocyte
number, 200 μl aliquots of adipocytes were fixed with osmic acid, incubated for 48 hours at
37°C and counted in a Coulter counter (Multisizer III, Beckman Coulter GmbH, Krefeld, Ger-
many). Histologic analyses and measurement of macrophage count in adipose tissue was per-
formed as previously described [17, 18]. In brief, adipose tissue samples were fixed at room
temperature in 4% formaldehyde and embedded in paraffin. Five-micrometer sections were
mounted on glass slides, deparaffinized in xylol, and stained for CD68 using anti-CD68 mono-
clonal mouse antihuman antibody (Dako, Glostrup, Denmark; close PGM1M0876, dilution
1:100). Macrophages were identified in the adipose parenchyma when cytoplasmic staining for
CD68 was present along with an identifiable mononuclear nucleus and presented as the num-
ber per 100 adipocytes (percent macrophages).
ADCY5 mRNA expression studies
Human ADCY5mRNA expression was measured by quantitative real-time RT-PCR in a fluo-
rescent temperature cycler using the TaqMan Gene Expression Assay Hs00766287_m1 that
contains premixed fluorescence labeled probes and TaqMan 2xUniversal PCR Master Mix
(Applied Biosystems, Darmstadt, Germany). Total RNA extracted from AT samples was isolat-
ed using TRIzol (Life Technologies, Grand Island, NY). 1μg RNA was reverse transcribed
using standard reagents (Life Technologies, Grand Island, NY). 2μl of each RT reaction was
amplified in a 26 μl PCR by using the Brilliant SYBR Green QPCR Core Reagent Kit from Stra-
tagene (La Jolla, CA, USA according to the manufacturer’s instructions. Samples were incubat-
ed in the ABI PRISM 7500 sequence detector for an initial denaturation at 95°C for 10min,
followed by 40 PCR cycles, each cycle consisting 95°C for 15s, 60°C for 1min, and 72°C for
1min. Probes were designed using standard Software (Applied Biosystems, Inc., Foster City,
CA). Expression of human ADCY5mRNA was quantified by using the second derivative maxi-
mummethod of the TaqMan Software (Applied Biosystems, Darmstadt, Germany) determin-
ing the crossing points of individual samples by an algorithm which identifies the first turning
point of the fluorescence curve. ADCY5mRNA expression was calculated relative to the
mRNA expression of Hypoxanthin-Guanin-Phosphoribosyltransferase 1 (HPRT1), determined
by a pre-developed TaqMan Assay (Hs01003267_m1; Applied Biosystems). Normalization by
endogenous control results in arbitrary units (AU). A detection limit cut off was defined at 36
cycles. Amplification of specific transcripts was confirmed by melting curve profiles (cooling
the sample to 68°C and heating slowly to 95°C with measurement of fluorescence) at the end of
each PCR. The specificity of the PCR was further verified by subjecting the amplification prod-
ucts to agarose gel electrophoresis.
Genotyping of the rs11708067 variant
Total genomic DNA from whole human blood samples was isolated using the Quickgene DNA
Whole Blood Kit according to the manufacturer’s instructions (Fujifilm, Düsseldorf, Deutsch-
land). The TaqMan SNP Genotyping assay (Applied Biosystems, Foster City, CA, USA) was
used in DNA samples to determine the respective genotypic groups. The allelic discrimination
reaction was performed according to the manufacturer's instructions on an ABI Prism 7500
ADCY5 in Obesity
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sequence detector (assay ID: C_8989067_10; Applied Biosystems, Foster City, CA, USA). Ge-
notype frequencies were in Hardy-Weinberg-equilibrium.
High fat diet study in C57BL/6NTac mice
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was ap-
proved by the local authorities of the state of Saxony, Germany (Landesdirektion, Regierung-
spräsidium Leipzig, Germany; Permit Number: T81/12) as recommended by the responsible
local animal ethics review board (Use of Laboratory Animals Ethics Committee of the Univer-
sity of Leipzig; registration number: TVV20/08). All efforts were made to minimize suffering.
All mice were housed in pathogen-free facilities in groups of three to four at 22 ± 2°C on a 12-h
light/dark cycle. C57BL/6NTac were bred and kept in the Animal Laboratories at the Universi-
ty of Leipzig. Animals had ad libitum access to water at all times. Twelve healthy lean male
C57BL/6NTac mice were randomized into an arm fed a high-fat diet (HFD) containing 55.2%
of calories from fat (C1057, Altromin) (N = 6) or to a standard chow diet (N = 6). After 10
weeks of high fat feeding, animals were sacrificed by an isoflurane overdose according to the
ARRIVE Guidelines (S1 Table) and paired samples of inguinal subcutaneous and epigonadal
adipose tissue were quickly removed. RNA isolation and quantitative real-time PCR was per-
formed as described above. The PCR was performed using 2 μl of sample from each reverse
transcription reaction in a final volume of 26 μl (Brilliant SYBR Green QPCR Core Reagent
Kit; Stratagene, La Jolla, CA). The following primer pairs were used: Adcy5, 5’- TGGAGATGG-
GAATGGACATGAT-3’ (sense) and 5’-CACGCGCATGTTCACGTT-30 (antisense). The
mRNA levels were quantified using the second derivative maximum method of the TaqMan
software (Applied Biosystems), determining the crossing points of individual samples by an al-
gorithm that identifies the first turning point of the fluorescence curve. Amplification of specif-
ic transcripts was confirmed by melting curve profiles (cooling the sample to 68°C and heating
slowly to 95°C with measurement of fluorescence) at the end of each PCR. Expression of the
normalization gene hypoxanthine phosphoribosyltransferase (HPRT) 1, was measured using
TaqMan Gene Expression Assays (Mm01545399_m1; Applied Biosystems).
Statistical analyses
Prior to statistical analysis, non-normally distributed parameters were log-transformed to ap-
proximate a normal distribution. Differences in genotype frequencies between the obese or
T2D cases and healthy control subjects were compared using logistic regression analyses. Ge-
notype-phenotype association analyses were done under the additive model and the presented
p values are adjusted for age and sex (and BMI for glucose traits). Results of univariate correla-
tion analysis were described with Pearson`s correlation coefficient. Differences in mRNA ex-
pression between VAT and SAT were assessed using paired Student’s t test. The analysis of
associations with quantitative traits was restricted to non-diabetic subjects to avoid diabetes
status or treatment masking potential effects of the variants on these phenotypic traits. Statisti-
cal analyses were performed using SPSS version 18.0.1 (SPSS; Inc., Chicago, IL, USA). p values
<0.05 were considered to be statistically significant.
Results and Discussion
Fat depot specific ADCY5 mRNA expression
We investigated ADCY5mRNA expression in visceral and subcutaneous adipose tissue in 244
individuals (157 women and 87 men), which have been further classified into patients with
ADCY5 in Obesity
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T2D (n = 80) or normal glucose metabolism (n = 164) (Table 1). In addition, we compared
subgroups of lean (BMI<25kg/m2, n = 43) and obese (BMI>30kg/m2, n = 175) individuals
(Table 1). In the analysis of the entire study cohort, we did not find significant differences be-
tween VAT and SAT ADCY5 expression (Fig. 1A). Independently of the fat depot, there were
also no differences in ADCY5 expression between men and women (Fig. 1B) and between pa-
tients with or without T2D (Fig. 1C). However, obese adipose tissue donors had significantly
higher VAT ADCY5 expression compared to lean individuals (Fig. 1D). Stratification of the
study participants into lean and obese also revealed significant fat depot specific ADCY5 ex-
pression differences with higher expression in VAT compared to SAT in obese and the oppo-
site significant difference in lean individuals (Fig. 1D).
Correlations of ADCY5 mRNA expression with parameters of obesity,
glucose metabolism and insulin sensitivity
ADCY5mRNA expression significantly correlates between VAT and SAT independently of
age, gender and BMI (Table 2). We found significant correlations of both VAT and SAT
ADCY5mRNA expression with body weight, BMI, % body fat, waist and hip circumferences,
and leptin serum concentrations (Table 2). In addition, VAT ADCY5 expression correlates
with height, abdominal visceral and subcutaneous fat areas, fat distribution (CT ratio) and
Fig 1. Adenylate cyclase 5 (ADCY5) mRNA expression in human abdominal visceral and
subcutaneous adipose tissue. ADCY5mRNA expression in adipose tissue (SAT, subcutaneous adipose
tissue; VAT, Visceral adipose tissue) from (A) the entire study cohort (n = 244), (B) 157 women and 87 men,
(C) individuals with type 2 diabetes (T2D, n = 80) or no diabetes (n = 164), (D) study participants with a
BMI<25kg/m2 (lean, n = 43) or BMI>30kg/m2 (obese, n = 175). ADCY5mRNA expression was calculated
relative to the expression of HPRT1 (AU = arbitrary units). All data are shown as mean ± SEM. *p<0.05 for
comparisons between VAT and SAT ADCY5 expression; ##p<0.01 for comparisons between lean and
obese individuals within each fat depot.
doi:10.1371/journal.pone.0120742.g001
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circulating adiponectin (Table 2). Only for SAT ADCY5 expression, we found significant rela-
tionships with age, serum triglycerides and HDL-cholesterol (Table 2). The correlations be-
tween VAT ADCY5 expression and visceral and subcutaneous fat areas, CT ratio, % body fat,
waist and hip circumferences, remained significant even after adjusting for age, gender and
BMI, whereas the univariate associations between SAT ADCY5 expression and body weight,
BMI, % body fat, waist and hip circumferences and leptin serum concentrations were indepen-
dent of age, gender and BMI (Table 2). Importantly, both in VAT and SAT, ADCY5 expression
was not significantly related to maximal (R2 = 0.03, p = 0.08) or mean adipocyte size (R2 =
0.012, p = 0.13) or macrophage infiltration into adipose tissue (R2 = 0.022, p = 0.07). We found
the same significant correlations between VAT and SAT ADCY5 expression after excluding in-
dividuals with T2D (data not shown).
Association of rs11708067 with obesity related quantitative traits and
ADCY5 mRNA expression
According to the rs11708067 genotype, we found significant differences between AA, AG and
GG carriers for fasting plasma glucose and triglycerides (Table 3). In addition, rs11708067 is
significantly associated with adiponectin serum concentration (p = 0.002, β = 0.587,
Table 2. Univariate correlations between ADCY5mRNA expression in visceral (VAT) and subcutane-
ous (SC) adipose tissue and parameters of obesity, insulin sensitivity, and inflammation.
Parameter SAT ADCY5 mRNAR2; p-value
(p-value adjusted for age, gender,
BMI)
VAT ADCY5 mRNAR2; p-value
(p-value adjusted for age, gender,
BMI)
SAT ADCY5 mRNA - 0.09; <0.001 (<0.001)
VAT ADCY5 mRNA 0.09; <0.001 (<0.001) -
Age (years) 0.02; 0.03 (n.a.) 0.016; 0.058 (n.a.)
Body weight (kg) 0.02; 0.013 (n.a.) 0.054; <0.001 (n.a.)
Height (m) 0.001; 0.621 (0.723) 0.03; 0.010 (n.a.)
BMI (kg/m2) 0.031; 0.008 (n.a.) 0.044; 0.002 (n.a.)
Visceral fat area (cm2) 0.011; 0.148 (0.190) 0.038; 0.007 (0.038)
SC fat area (cm2) 0.009; 0.183 (0.326) 0.065; <0.001 (0.003)
CT ratio 0.002; 0.538 (0.988) 0.048; 0.002 (0.014)
Body fat (%) 0.051; 0.005 (0.077) 0.041; 0.013 (0.02)
Waist (cm) 0.017; 0.047 (0.140) 0.047; 0.001 (0.01)
Hip (cm) 0.031; 0.008 (0.071) 0.061; <0.001 (0.001)
Fasting plasma glucose
(mmol/l)
0.00003; 0.925 (0.866) 0.006; 0.226 (0.24)
HbA1c (%) 0.001; 0.612 (0.914) 0.0006; 0.716 (0.059)
Triglycerides (mmol/l) 0.035; 0.029 (0.142) 0.004; 0.446 (0.097)
HDL-cholesterol (mmol/l) 0.031; 0.044 (0.882) 0.001; 0.255 (0.839)
Adiponectin (μg/ml) 0.007; 0.297 (0.357) 0.018; 0.04 (0.579)
Leptin (pg/ml) 0.025; 0.044 (0.755) 0.038; 0.012 (0.072)
R2, Pearson0s correlation coefficient. Analyses were performed only in individuals for which complete data
sets were available (n = 240). Significant associations are highlighted in bold if they remained significant
after adjusting for age, gender and BMI (in brackets: p-values adjusted for BMI, age, and gender).
Significant associations after adjustment are highlighted in bold. (data are log transformed). FPG, fasting
plasma glucose; n.a., not applicable.
doi:10.1371/journal.pone.0120742.t002
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SE = 0.233, adjusted for age and gender). In contrast to that, we did not find significant associa-
tions between rs11708067 and BMI (p = 0.336), WHR (p = 0.155), HDL-cholesterol
(p = 0.846), LDL-cholesterol (p = 0.255), total cholesterol (p = 0.638), triglycerides (p = 0.759),
fasting plasma insulin (p = 0.295), HbA1c (p = 0.076), 2hOGTT (p = 0.494), leptin serum con-
centration (p = 0.311), creatinine (p = 0.758) and % body fat (p = 0.989).
Analyses of ADCY5mRNA in VAT and SAT identified significant expression differences as
a function of the rs11708067 genotype (Table 3). However, rs11708067 is not associated with
ADCY5mRNA expression levels in either fat depot in any of the genetic models tested (addi-
tive, dominant/recessive; all P>0.05 after adjusting for age, sex and BMI). In addition, we per-
formed interaction analyses to test whether there is a statistically plausible interaction between
Table 3. Anthropometric andmetabolic characteristics of participants in the study of adipose tissue
ADCY5mRNA expression according to the rs11708067 genotype.
rs11708067 genotype: AA AG GG
N 150 85 9
SAT ADCY5 mRNA (AU/HPRT) 3.21±0.5* 4.19±0.7 3.09±1.5
VAT ADCY5 mRNA (AU/HPRT) 3.55±0.8 3.35±0.7 1.61±1.4#,§
Age (years) 50±15.7 52±13.5 47±15.0
Body weight (kg) 118.2±45.3 123.5±38.8 117.0±51.2
Height (m) 1.70±0.1 1.70±0.1 1.70±0.1
BMI (kg/m2) 41.0±14.6 42.6±12.6 40.3±16.7
Visceral fat area (cm2) 259.0±183.1 246.2±176.4 293.1±195.0
SC fat area (cm2) 1211.4±805.1 1125.1±798.9 1615.4±398.9
CT ratio 0.4±0.5 0.5±0.7 0.2±0.1
Body fat (%) 36.6±11.9 36.2±11.3 31.0±14.4
Waist (cm) 119.8±33.4 125.2±29.3 122.4±40.7
Hip (cm) 128±21.7 132.9±27.6 128.3±34.5
WHR 0.9±0.1 0.9±0.1 0.9±0.1
Fasting plasma glucose (mmol/l) 5.8±1.2 6.3±1.8* 8.1±3.9#, §
Fasting plasma insulin (mmol/l) 79.8±109.4 95.2±110.3 69.6±49.2
HbA1c (%) 5.9±1.1 6.0±0.9 6.1±0.6
2h oGTT glucose (mmol/l) 6.7±2.7 7.3±3.1 7.4±0.5
Clamp GIR (μmol/kg/min) 78.6±33.7 73.2±33.3 84.0±40.4
Creatinine (μmol/l) 83.8±51.7 78.5±26.4 95.5±39.2
hsCRP (mg/l) 4.9±1.4 6.1±1.5 3.2±3.5
Triglycerides (mmol/l) 1.5±0.9 1.7±1.0 2.2±1.3#, §
Cholesterol (mmol/l) 5.0±1.0 5.0±0.9 4.9±1.0
HDL-cholesterol (mmol/l) 1.4±0.4 1.4±0.5 1.4±0.1
LDL-cholesterol (mmol/l) 3.1±1.0 3.3±0.7 3.6±1.7
Adiponectin (μg/ml) 7.6±4.6 7.4±4.5 7.3±7.4
Leptin (pg/ml) 32.8±20.7 39.6±22.6 38.4±28.9
Data are means ± SD.
*p<0.05 for comparisons between AA and AG genotypes,
#p<0.05 for comparisons between AA and GG genotypes,
§ p<0.05 for comparisons between AG and GG genotypes.
BMI, body mass index, WHR, waist-hip ratio, 2h oGTT, 2 hour oral glucose tolerance test, GIR, glucose
infusion rate, hsCRP, high sensitive C-reactive protein, HDL, high-density lipoprotein, LDL, low-density
lipoprotein, SC subcutaneous, SAT, subcutaneous adipose tissue, VAT, visceral adipose tissue
doi:10.1371/journal.pone.0120742.t003
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BMI, age, sex and the genotype for ADCY5mRNA. Importantly, none of these interaction tests
was significant for either subcutaneous or visceral ADCY5mRNA as outcome variables (i.e. a
total of six tests; all p>0.05).
High fat feeding increases adipose tissue ADCY5 mRNA expression in
mice
In C57BL/6NTac, Adcy5mRNA expression was detectable in subcutaneous inguinal and epi-
gonadal AT depots with significantly lower expression in epigonadal compared to subcutane-
ous AT independently of the diet intervention (Fig. 2). Importantly, high fat feeding over 10
weeks resulted in significantly higher ADCY5mRNA levels in both AT depots (Fig. 2).
Discussion
In the current study, we analyzed relationships between ADCY5mRNA expression in human
visceral and subcutaneous adipose tissue, metabolic traits related to obesity and the ADCY5 ge-
notype at the risk SNP rs11708076. In addition, we tested the hypothesis that Adcy5 expression
in adipose tissue of mice is altered by high fat feeding. We found significantly higher ADCY5
expression in VAT from obese compared to that of lean individuals. We report here that
ADCY5 expression is strongly related to obesity and fat distribution, because both VAT and
SAT ADCY5 correlate with body weight, BMI, % body fat, waist and hip circumferences, and
leptin serum concentrations. These data raise the question whether ADCY5 expression changes
in AT may together with previously reported ADCY5 expression changes at the level of beta
cells [2] contribute to obesity related deterioration of glucose metabolism and T2D. However,
we did not find significant relationships between ADCY5 AT expression and parameters of im-
paired glucose metabolism (fasting plasma glucose and HbA1c). Moreover, patients with T2D
did not appear to have higher AT ADCY5 expression and neither VAT or SAT. Therefore, it is
unlikely that the previously reported association between the ADCY5 genotype, higher fasting
glucose and increased T2D risk [1] is mediated by ADCY5 expression changes in AT.
Fig 2. Adcy5mRNA expression in adipose tissue of C57BL/6 mice on either chow or high fat diet
(HFD). Adcy5mRNA expression was calculated relative to the expression of 18S rRNA (AU = arbitrary units).
*p<0.05; **p<0.01 for comparisons between chow and HFD; #p<0.05 for comparisons between fat depots.
SAT, subcutaneous adipose tissue; EPI AT, epigonadal adipose tissue.
doi:10.1371/journal.pone.0120742.g002
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Importantly, the cross-sectional design of our study does not allow to draw direct conclusions
regarding the causative chain, i.e. whether changes in ADCY5mRNA expression precede meta-
bolic alterations or vice versa. The observation that only in obese subjects ADCY5mRNA was
differentially expressed between SAT and VAT suggests that changes in ADCY5 expression
occur secondary to deterioration of the metabolic profile.
It has been recently reported that SNPs in ADCY5 (e. g. rs11708076, rs9883204) were associ-
ated with T2D [1], decreased pancreatic islet ADCY5 expression [2], gestational diabetes [4],
and lower birth weight [3, 19, 20]. The association with birth weight does not seem to be as ro-
bust as the association with T2D, because a recent study [21] could not confirm the birth
weight lowering effects of rs9883204, which is in linkage disequilibrium (LD) with rs11708067.
A limited sample size and a specific genetic background of the studied Asian population might
explain the observed discrepancy [21]. Nevertheless, associations with lower birth weight
would support the “fetal insulin hypothesis” by indicating that beta cell function may already
be present in pre-natal life [22]. Noteworthy, the ADCY5 risk SNP rs11708067 has been shown
to be associated with impaired proinsulin-insulin conversion. [23]. Moreover, Windholz et al.
[5] reported associations of the ADCY5 rs2877716 variant—which is in LD with rs11708067
tested in our work—with parameters of insulin secretion and action (fasting plasma insulin,
peak insulin, QUICKI and Matsuda insulin sensitivity index), but not with obesity related traits
in obese Caucasian children.
We have to acknowledge, that we could not confirm previously reported associations be-
tween rs11708067 and fasting glucose or fasting insulin. This is most likely due to the relatively
small sample size (n = 244) and limited statistical power, which may also have been missed in
correlation analyses between the ADCY5 genotype and the ADCY5mRNA expression in adi-
pose tissue. However, carriers of the GG rs11708067 genotype (n = 9) had significantly lower
ADCY5 VAT expression which supports the notion that this risk genotype also leads to de-
creased expression in islets [2]. Since this effect was not seen in SAT, the ADCY5 genotype
might indirectly contribute to increased T2D risk by promoting visceral fat distribution. Our
feeding studies in mice demonstrate that Adcy5 expression in AT are increasing with high fat
diet. These data strongly support the hypothesis that changes in AT ADCY5 expression may
link obesity to T2D. Further studies should investigate whether subsequent changes in adipose
tissue morphology (e.g. adipocyte hypertrophy, AT immune cell infiltration) and function are
related to ADCY5 expression and or the ADCY5 genotype. In our study, the sample size was
too low to establish such relationships, although non-significant trends could be found for an
association between AT ADCY5 expression, adipocyte size (p = 0.07) and number of macro-
phages in AT (p = 0.08). Yet, the observed association of rs11708067 with adiponectin serum
concentration is at least suggestive for a causal relationship between ADCY5 genotype, ADCY5
expression and adipose tissue function. Together with the human genotype—ADCY5 expres-
sion data, we postulate that the ADCY5 genotype may modulate the fat depot specific response
to high calorie intake.
Conclusions
Our data do not support the hypothesis that ADCY5 polymorphisms contribute to altered
ADCY5 gene expression in AT. However, independently of the ADCY5 genotype, AT ADCY5
expression is related to obesity and may contribute to adverse fat distribution and adipose tis-
sue dysfunction. Moreover, our mouse feeding studies suggest that high fat intake may modu-
late adipose tissue function by increasing expression of Adcy5. However, the association
between rs11708067, elevated fasting glucose and increased T2D risk detected in genome wide
association studies does not seem to be due to ADCY5 expression changes in adipose tissue.
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